巴曲酶与阿加曲班联合用药方案治疗急性缺血性脑卒中的临床效果及安全性评价

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (31 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical efficacy and safety of Batroxobin combined with Agatroban in the treatment of acute ischemic stroke, so as to provide references for clinicians to choose rational drug regimens. Methods A total of 80 patients with acute ischemic stroke admitted to Liaoyang Central Hospital from April 2018 to July 2019 were selected as the study subjects. According to the random number table method, the subjects were divided into the experimental group and the control group, 40 cases in each group. The control group was given routine treatment, and the experimental group was given the combination of Batroxobin and Agatroban based on the control group. The total effective rate of clinical treatment, National Institute of Health stroke scale (NIHSS) score and incidence of adverse reactions were compared between the two groups. Results The total clinical effective rate of the experimental group(92.50%) was higher than that of the control group (75.00%), the difference was statistically significant (P＜0.05). The NIHSS scores of the patients in the two groups after treatment were lower than those before treatment, and the NIHSS score of the experimental group was lower than that of the control group, the differences were statistically significant(P＜0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P＞0.05).Conclusion In the treatment of patients with acute ischemic stroke, the combination of Batroxobin and Agatroban has ideal clinical effect, and can effectively improve the neurological deficit without increasing adverse reactions, which is worthy of recommendation.

Key words： Acute ischemic stroke Batroxobin Agatroban Neurological deficit Clinical effect Adverse reactions

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	ZHANG Jing-xin

Cite this article:

ZHANG Jing-xin. Clinical efficacy and safety evaluation of Batroxobin combined with Agatroban in the treatment of acute ischemic stroke[J]. 中国当代医药, 2020, 27(7): 69-71.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2020/V27/I7/69

[1]	宋凯悦.巴曲酶与阿加曲班治疗急性大动脉粥样硬化性脑梗死的疗效观察[D].大连：大连医科大学，2018.
[2]	潘辉.巴曲酶联合阿加曲班治疗急性进展性脑梗死的疗效观察[J].实用心脑肺血管病杂志，2014，22（3）：7-8.
[3]	王宏艳，高志欣，李玮.阿加曲班注射液治疗急性脑梗死患者的疗效观察[J].现代药物与临床，2013，28（4）：581-584.[4]伍俊，翟月萍，李鑫铭.阿加曲班治疗急性缺血性脑卒中的疗效[J].临床医学研究与实践，2018，3（12）：8-9，18.
[5]	宋登花.静脉注射阿加曲班治疗动脉粥样硬化型脑梗死早期疗效观察[J].基层医学论坛，2018，22（23）：3240-3241.
[6]	中华医学会神经病学分会，中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志，2018，51（9）：666-682.
[7]	中国老年医学学会急诊医学分会，中华医学会急诊医学分会卒中学组，中国卒中学会急救医学分会.急性缺血性脑卒中急诊急救中国专家共识2018[J].中国卒中杂志，2018，13（9）：956-967.
[8]	初婷婷，叶琳琳，郑永慧，等.巴曲酶联合阿加曲班治疗短暂性脑缺血发作200 例[J].中国老年学杂志，2015，（14）：3896-3897.
[9]	徐斌，赵海玲，张勇，等.不同药物治疗进展性脑梗死观察[J].海南医学院学报，2013，19（2）：191-193.
[10]	吴玉波，王伟巍，李岩，等.巴曲酶和阿加曲班治疗急性缺血性脑卒中的最小成本分析[J].中国药师，2011，14（7）：1025-1026.
[11]	吴玉波，王伟巍，李岩，等.3 种治疗急性缺血性脑卒中药的最小成本分析[J].中国药房，2011，22（10）：865-866.
[12]	柳迎春.阿加曲班治疗急性缺血性脑卒中的有效性及安全性[J].武警医学，2015，26（2）：124-126.
[13]	吕鸿杰.阿加曲班序贯于巴曲酶治疗急性缺血性卒中的临床观察[J].神经损伤与功能重建，2011，6（4）：246-249.
[14]	张彦朋，马弯弯，张艳丽，等.巴曲酶治疗急性缺血性脑卒中临床疗效的Meta 分析[J].中国临床研究，2017，30（6）：782-788.
[15]	李雪娇.阿加曲班治疗急性缺血性脑卒中的临床效果分析[J].中国疗养医学，2018，27（4）：412-413.